검색어 : 통합검색[Rock Garrett.]
총 84건 중 84건 출력
, 9/9 페이지
-
81
- Allelic Variants in <i>Arhgef11</i> via the Rho-Rock Pathway Are Linked to Epithelial–Mesenchymal Transition and Contributes to Kidney Injury in the Dahl Salt-Sensitive Rat
- Jia, Zhen; Johnson, Ashley C.; Wang, Xuexiang; Guo, Zibiao; Dreisbach, Albert W.; Lewin, Jack R.; Kyle, Patrick B.; Garrett, Michael R.; Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, MS, United States of America; Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, MS, United States of America; Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, MS, United States of America; Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, MS, United States of America; Department of Medicine (Nephrology), University of Mississippi Medical Center, Jackson, MS, United States of America; Department of Pathology, University of Mississippi Medical Center, Jackson, MS, United States of America; Department of Pathology, University of Mississippi Medical Center, Jackson, MS, United States of America; Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, MS, United States of America; (PloS one, v.10, 2015, pp.e0132553)
-
82
- A first-in-human study of the dual ROCK I/II inhibitor, AT13148, in patients with advanced cancers.
- Papadatos-Pastos, Dionysios; Kumar, Rajiv; Yap, Timothy Anthony; Ruddle, Ruth; Decordova, Shaun; Jones, Paul; Halbert, Gavin; Garrett, Michelle D; McLeod, Robert; Backholer, Zoe; Swales, Karen E; Raynaud, Florence I.; De Bono, Johann Sebastian; Banerji, Udai; The Institute of Cancer Research and The Royal Marsden, London, United Kingdom; The Institute of Cancer Research and The Royal Marsden, London, United Kingdom; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; The Institute of Cancer Research, London, United Kingdom; The Institute of Cancer Research and The Royal Marsden, London, United Kingdom; Cancer Research UK Centre for Drug Development, London, United Kingdom; Cancer Research UK Strathclyde Formulation Unit, Glasgow, United Kingdom; The Institute of Cancer Research, London, United Kingdom; Cancer Research UK Centre for Drug Development, London, United Kingdom; Cancer Research UK Centre for Drug Development, London, United Kingdom; The Institute of Cancer Research, London, United Kingdom; The Institute of Cancer Research and The Royal Marsden, London, United Kingdom; The Institute of Cancer Research and The Royal Marsden, London, United Kingdom; The Institute of Cance; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.33, 2015, pp.2566-2566)
-
83
- Associations of Early Completion of Advance Directives With Key End-of-Life Quality Measures: Analysis of an ASCO Quality Oncology Practice Initiative Patient Cohort
- Power, Steve; Bickel, Kathleen; Chen, Ronald C.; Chiang, Anne C.; Garrett-Mayer, Liz; Makhoul, Issam; Mougalian, Sarah S.; Shapiro, Charles L.; Siegel, Robert; Smith, Cardinale; Rocque, Gabrielle B.; Kozlik, Mary May; Crist, Sté phanie T.S.; Kamal, Arif; Duke Cancer Institute, Duke University Medical Center, Durham, NC; University of Colorado Anschutz Medical Campus, Aurora, CO; University of Kansas School of Medicine, Kansas City, KS; Yale University School of Medicine, New Haven, CT; American Society of Clinical Oncology, Alexandria, VA; CARTI, Central Arkansas Radiation Therapy Institute, Little Rock, AR; Yale University School of Medicine, New Haven, CT; Icahn School of Medicine at Mount Sinai, New York, NY; Bon Secours St Francis Cancer Center, Greenville, SC; Icahn School of Medicine at Mount Sinai, New York, NY; University of Alabama at Birmingham, Department of Medicine, Division of Hematology and Oncology, Birmingham, AL; American Society of Clinical Oncology, Alexandria, VA; American Society of Clinical Oncology, Alexandria, VA; Duke Cancer Institute, Duke University Medical Center, Durham, NC; (JCO oncology practice, v.19, 2023, pp.e520-e526)
-
84
- First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors
- McLeod, Robert; Kumar, Rajiv; Papadatos-Pastos, Dionysis; Mateo, Joaquin; Brown, Jessica S.; Garces, Alvaro H. Ingles; Ruddle, Ruth; Decordova, Shaun; Jueliger, Simone; Ferraldeschi, Roberta; Maiques, Oscar; Sanz-Moreno, Victoria; Jones, Paul; Traub, Stephanie; Halbert, Gavin; Mellor, Sarah; Swales, Karen E.; Raynaud, Florence I.; Garrett, Michelle D.; Banerji, Udai; Cancer Research UK, London, United Kingdom.; The Royal Marsden NHS Foundation Trust, London, United Kingdom.; The Royal Marsden NHS Foundation Trust, London, United Kingdom.; The Royal Marsden NHS Foundation Trust, London, United Kingdom.; The Royal Marsden NHS Foundation Trust, London, United Kingdom.; The Royal Marsden NHS Foundation Trust, London, United Kingdom.; The Institute of Cancer Research, London, United Kingdom.; The Institute of Cancer Research, London, United Kingdom.; Astex Pharmaceuticals, Cambridge, United Kingdom.; Astex Pharmaceuticals, Cambridge, United Kingdom.; Bart's Cancer Centre, Queen Mary University of London, London, United Kingdom.; Bart's Cancer Centre, Queen Mary University of London, London, United Kingdom.; Cancer Research UK, London, United Kingdom.; Cancer Research UK, London, United Kingdom.; Strathclyde Institute of Pharmacy and Biomedical Sciences, Glasgow, United Kingdom.; Cancer Research UK, London, United Kingdom.; The Institute; (Clinical Cancer research : an official journal of the American Association for Cancer Research, v.26, 2020, pp.4777-4784)
QUICK MENU
